Basic information
| Product Name | Catalog | Type | Host/Source | Usage | Applications | COA |
| HCV Core-NS3-NS5 fusion antigen | BMEHCV113 | Antigen | Ecoli | Capture | ELISA, CLIA, WB | Download |
| HCV Core-NS3-NS5 fusion antigen | BMEHCV114 | Antigen | Ecoli | Conjugate | ELISA, CLIA, WB | Download |
| HCV Core-NS3-NS5 fusion antigen-Bio | BMEHCVB01 | Antigen | Ecoli | Conjugate | ELISA, CLIA, WB | Download |
The main infectious sources of hepatitis C are acute clinical type and asymptomatic subclinical patients, chronic patients and virus carriers. The blood of the general patient is infectious 12 days before the onset of the disease, and can carry the virus for more than 12 years. HCV is mainly transmitted from blood sources. In foreign countries, 30-90% of post transfusion hepatitis is hepatitis C, and in China, hepatitis C accounts for 1/3 of post transfusion hepatitis. In addition, other methods can be used, such as mother to child vertical transmission, family daily contact and sexual transmission.
When plasma or blood products containing HCV or HCV-RNA are infused, they usually become acute after 6-7 weeks of incubation period. The clinical manifestations are general weakness, poor gastric appetite, and discomfort in the liver region. One third of patients have jaundice, elevated ALT, and positive anti HCV antibody. 50% of clinical hepatitis C patients can develop into chronic hepatitis, even some patients will lead to liver cirrhosis and hepatocellular carcinoma. The remaining half of the patients are self limited and can recover automatically.
